{"ticker": {"uuid": "8c6e737f-5983-456d-8998-ea370b378370", "symbol": "BCRX", "name": "BioCryst Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "BioCryst Appoints David W. Jenkins as Chief Scientific Officer", "summary": "BioCryst Pharmaceuticals has announced the appointment of David W. Jenkins as its new Chief Scientific Officer. This strategic hire is expected to bolster the company's research and development initiatives. Jenkins brings a wealth of experience to the role, which will be crucial ", "url": "https://www.moomoo.com/news/post/73006044/biocryst-appoints-david-w-jenkins-as-chief-scientific-officer?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T12:17:28", "published_display": "15 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst\u2019s New Science Chief Brings Over 20 Years in Biopharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOTmx5djVrLXlfdE9GS25tc21CTWZYanpIak9XLV9xRTdfaEZsT1VQakRmVUR1cW9Zc3VHVUdvaUpzQ1dURHN6TEZ2WFdLd0NZSUdEelNHYWdYT3pDV2UzU0I0UzJaNTlEdGJVSWtvc0RTa0o5WTZFY3FEUUdNaHdCN0tpSjkxQWs5S3pCQVNxYjZ6aUwxNENXbzJRR1J4YTRZc3VMajNjY19YWllBZ2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:04:58+00:00", "published_display": "15 Jul 2026 11:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst names David Jenkins as chief scientific officer", "summary": "BioCryst Pharmaceuticals has appointed David Jenkins as its new Chief Scientific Officer, effective immediately. Jenkins, with over 20 years of experience, will lead external innovation and partnerships for rare disease therapies, signaling a strategic shift for BioCryst. The com", "url": "https://www.investing.com/news/company-news/biocryst-names-david-jenkins-as-chief-scientific-officer-93CH-4792915", "source_name": "Investing.com", "published_at": "2026-07-15T11:17:28", "published_display": "15 Jul 2026 11:17", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Appoints David Jenkins as Chief Scientific Officer | BCRX Stock News", "summary": "BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed David W. Jenkins, MA, PhD, as its first Chief Scientific Officer, effective immediately. Dr. Jenkins, with over 20 years of biopharmaceutical R&D experience, will lead a research team focused on external innovation, capabiliti", "url": "https://www.stocktitan.net/news/BCRX/bio-cryst-appoints-david-w-jenkins-as-chief-scientific-k0283wflxy2s.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:17:28", "published_display": "15 Jul 2026 11:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals Names David W. Jenkins Chief Scientific Officer to Lead External Innovation Strategy", "summary": "BioCryst Pharmaceuticals has appointed David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, a role focused on leading external innovation and partnerships to accelerate the development of rare disease therapies. Dr. Jenkins, with over 20 years of biopharmaceutical indu", "url": "https://www.quiverquant.com/news/BioCryst+Pharmaceuticals+Names+David+W.+Jenkins+Chief+Scientific+Officer+to+Lead+External+Innovation+Strategy", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T11:13:00", "published_display": "15 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure", "summary": "BioCryst Pharmaceuticals (BCRX) stock appears undervalued despite a 40% five-year decline, trading at a P/S ratio of 2.8x compared to an industry average of 11.2x. The company's shift towards external innovation and partnerships, coupled with takeover speculation, suggests potent", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/biocryst-bcrx-stock-looks-like-a-bargain-after-facility-clos", "source_name": "Simply Wall Street", "published_at": "2026-07-15T01:10:33", "published_display": "15 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-biocryst-135503464.html", "source_name": "Zacks", "published_at": "2026-07-14T13:55:03+00:00", "published_display": "14 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Coverage Resumed by JPMorgan with Neutral Rating", "summary": "JPMorgan has resumed coverage of BioCryst Pharmaceuticals, Inc. (BCRX) with a Neutral rating and a $12 price target, noting that significant appreciation hinges on the successful launch of navenibart. The company holds a GF Score of 66/100, indicating moderate potential for long-", "url": "https://www.gurufocus.com/news/8954989/biocryst-bcrx-coverage-resumed-by-jpmorgan-with-neutral-rating", "source_name": "GuruFocus", "published_at": "2026-07-13T10:39:53", "published_display": "13 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes BioCryst Pharma stock coverage with neutral rating By Investing.com", "summary": "JPMorgan has resumed coverage of BioCryst Pharma (NASDAQ:BCRX) with a Neutral rating and a $12.00 price target for December 2027. The firm's outlook is based on BioCryst's strategic shift to a business development-driven model, particularly following the acquisition of Astria and", "url": "https://ca.investing.com/news/stock-market-news/jpmorgan-resumes-biocryst-pharma-stock-coverage-with-neutral-rating-93CH-4730322", "source_name": "Investing.com Canada", "published_at": "2026-07-13T08:39:53", "published_display": "13 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Cantor Global Healthcare Conference 2025 Summary", "summary": "BioCryst Pharmaceuticals (BCRX) provided an update at the Cantor Global Healthcare Conference 2025, highlighting strong growth projections for its drug ORLADEYO, with anticipated sales reaching $580\u2013$600 million this year and potentially $1 billion by the decade's end. The compan", "url": "https://quartr.com/events/biocryst-pharmaceuticals-inc-bcrx-cantor-global-healthcare-conference-2025_of73Ufyy", "source_name": "Quartr", "published_at": "2026-07-13T07:40:43", "published_display": "13 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Proxy filing Summary", "summary": "BioCryst Pharmaceuticals' (BCRX) proxy filing outlines the agenda for its Annual Meeting on June 11, 2026, which includes the election of three directors, ratification of Ernst & Young LLP as auditors, an advisory vote on executive compensation, and approval of an amended Stock I", "url": "https://quartr.com/events/biocryst-pharmaceuticals-inc-bcrx-proxy-filing_of73yeJk", "source_name": "Quartr", "published_at": "2026-07-13T07:40:43", "published_display": "13 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus", "summary": "BioCryst Pharmaceuticals (BCRX) is discontinuing internal discovery programs and closing its Discovery Center of Excellence to refocus R&D efforts. Despite mixed long-term returns, the stock is considered 50.9% undervalued with a fair value of $21.30, largely due to strong revenu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/biocryst-pharmaceuticals-bcrx-reshapes-r-and-d-as-fair-value/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-13T01:40:44", "published_display": "13 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow, S&P 500, Nasdaq Futures Flip Early Gains As Iran Talk Optimism Cools: Why VCX, MU, BCRX, CMCL, DKNG Are Trending After-Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQTjZPS01ORmdHdnNxYmJKeTNYSnRrVHBvUXZWNnViSFNGQnJwNTlVa1V1QTZDUy1XOFJ2Rmdfek5xbDZwNnZqbE1LQjZscHVVbFlOck02S3NXeWNWWHZDeXl3TVUtcGptNnVBN1dIN0NOaFRiZVplYnJucUV1VmZtWUIwcHlNSWF5bVJvb3VtT1h1cWRNc2J0a0tJVkZFWTlpZ3ZSajRIYVlmMUczUjNfc2dBaVhDOGplbFJqdlk3empaOV9YbTVfWm9mejloRkd3ZjNUYlhIYW4xM3Yw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T17:34:29+00:00", "published_display": "12 Jul 2026 17:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BCRX) Movement Within Algorithmic Entry Frameworks", "summary": "This article from Stock Traders Daily discusses Biocryst Pharmaceuticals Inc. (BCRX) and presents various algorithmic trading strategies. It highlights strong sentiment across all horizons supporting an overweight bias, with no resistance levels identified above the current price", "url": "https://news.stocktradersdaily.com/news_release/78/BCRX_Movement_Within_Algorithmic_Entry_Frameworks_071126103002_1783823402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T22:09:41", "published_display": "11 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?", "summary": "BioCryst Pharmaceuticals announced it would discontinue its internal drug discovery programs and close its Birmingham Discovery Center by the end of 2026, shifting towards external innovation and partnerships for its rare disease pipeline. This strategic pivot aims to create a mo", "url": "https://www.sahmcapital.com/news/content/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durable-rare-disease-innovation-model-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-11T00:40:55", "published_display": "11 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock information for BioCryst Pharmaceuticals Inc. (BCRX), including its current stock price and recent performance. It also indicates that there are currently no analyst ratings or detailed earnings information available for the company. The page is part", "url": "https://timothysykes.com/quote/BCRX/", "source_name": "timothysykes.com", "published_at": "2026-07-10T00:11:28", "published_display": "10 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNeGtsSFM2bTB5MlJ2UU1ZOXdWZjJkdkZCZjhQaDhPTlgzWkJvOHNaeWJ0Mk5OdDVVZndETUZkbFNuTElacktTVlZwSk12Vm11M2w1Ul9TdzltQXFXb0ZNVGJPZ0ZoZ1RZSmJLRXhzUVFZRVl3QjZpbmIyTjBDbXlWT05ZUVJVbDlfSVVIalhPTHhjZTFDVU0xakQxTkI?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:13:23+00:00", "published_display": "09 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?", "summary": "Shares of Penguin Solutions Inc. (PENG), Arista Networks Inc. (ANET), and Biocryst Pharmaceuticals Inc. (BCRX) reached 52-week highs due to positive catalysts and increased price targets from Wall Street analysts. PENG benefited from increased AI demand and analyst upgrades, ANET", "url": "https://www.tradingview.com/news/stocktwits:13544c290094b:0-why-did-peng-anet-bcrx-shares-surge-to-52-week-highs/", "source_name": "TradingView", "published_at": "2026-07-09T03:39:32", "published_display": "09 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOR3JkbnhDbkU5SkRrUkxyYjlORVBoVWRyNzNacWFGdWkwbUZiM3loUWUwdTZOZjVRWFJkUTZrRkxlTTZYRkQ5YTdTR0p4M3B5SHZBbnlSb0t0WEJMQnRpNEFGQ3pITHlzRDVEZ2JzdzdHQzNhc1VkWkc5RzFvdGh1eVFYQVp5ZzJoQ1hHb3lRZHJqVVZFWXVSQURpRy1jWU8wWnI3UDJ4VQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T02:11:00+00:00", "published_display": "09 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?", "summary": "BioCryst Pharmaceuticals (BCRX) shares surged 8.1% due to strong performance of its marketed therapies like Orladeyo and Rapivab, and a promising rare disease-focused pipeline. The company is expected to post favorable quarterly earnings and revenue growth, with positive trends i", "url": "https://finance.yahoo.com/markets/stocks/articles/biocryst-bcrx-surges-8-1-141400956.html", "source_name": "Market source", "published_at": "2026-07-08T14:10:51", "published_display": "08 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD", "summary": "BioCryst Pharmaceuticals (BCRX) stock reached a 52-week high of $10.94, reflecting a 22.01% increase over the last year and strong recent momentum with a 30% year-to-date gain. Despite this, InvestingPro analysis suggests the stock might be overvalued. The company recently report", "url": "https://www.investing.com/news/company-news/biocryst-pharmaceuticals-stock-hits-52week-high-at-1094-usd-93CH-4779927", "source_name": "Investing.com", "published_at": "2026-07-08T00:10:52", "published_display": "08 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD By Investing.com", "summary": "BioCryst Pharmaceuticals Inc. (BCRX) stock recently hit a new 52-week high of $10.94, marking a 22.01% increase over the last year and strong year-to-date and six-month returns. This surge reflects investor confidence and strategic company advancements, despite a significant Q1 2", "url": "https://m.au.investing.com/news/stock-market-news/biocryst-pharmaceuticals-stock-hits-52week-high-at-1094-usd-93CH-4521911?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-07T20:41:07", "published_display": "07 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery, Is The Stock Still Undervalued?", "summary": "BioCryst Pharmaceuticals (BCRX) is transitioning its research model by concluding internal discovery programs and focusing on externally sourced rare disease projects. Despite a 39.85% decrease in its 5-year total shareholder return, the stock has seen recent gains of 17.0% (30-d", "url": "https://www.sahmcapital.com/news/content/biocryst-pharmaceuticals-bcrx-ends-internal-discovery-is-the-stock-still-undervalued-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-07T12:10:15", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for BioCryst Pharmaceuticals (NASDAQ:BCRX) to $14 from $13, while reiterating an Outperform rating on the stock. This adjustment suggests an updated positive outlook from the firm regarding BioCryst's future performance.", "url": "https://www.moomoo.com/news/post/72582569/rbc-capital-adjusts-biocryst-pharmaceuticals-price-target-to-14-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T11:41:07", "published_display": "07 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCRX - Biocryst Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a comprehensive overview of BioCryst Pharmaceuticals Inc. (BCRX), detailing its recent stock performance, key financial metrics, volatility indicators, and various valuation ratios. It covers aspects from market capitalization and sales to insider ownership ", "url": "https://finviz.com/stock?t=BCRX&ta=1&p=d&ty=ocv&r=m3&ov=list_strike&s=3", "source_name": "Finviz", "published_at": "2026-07-05T23:39:09", "published_display": "05 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Biocryst Pharmaceuticals Inc (BCRX)", "summary": "This article examines the historical returns of investing $1,000 in Biocryst Pharmaceuticals Inc (BCRX) over 1, 5, and 10 years, noting a 12.3% total return in the last year and a 235.8% return over ten years. It provides annual performance data for BCRX against the S&P 500 and a", "url": "https://www.stocktitan.net/tools/stock-return-calculator/BCRX", "source_name": "Stock Titan", "published_at": "2026-07-04T07:11:07", "published_display": "04 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmaceutical company closing Birmingham facility", "summary": "BioCryst Pharmaceuticals, a North Carolina-based company founded in Birmingham, announced it will close its Birmingham Discovery Center of Excellence facility and discontinue internal discovery programs by the end of the year. The company plans to shift its focus to external rese", "url": "https://www.al.com/business/2026/06/pharmaceutical-company-closing-birmingham-facility.html", "source_name": "AL.com", "published_at": "2026-07-02T23:43:47", "published_display": "02 Jul 2026 23:43", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to nine newly-hired employees. These grants, totaling 33,950 stock options and 91,750 RSUs, were made on July 1, 2026, as inducements in accordance wit", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377418/amp", "source_name": "The Manila Times", "published_at": "2026-07-02T19:40:34", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story", "summary": "BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Birmingham Discovery Center, shifting its focus to externally sourced innovation for its rare disease pipeline. This move redefines the company's investment narrative, emphasizing execution ", "url": "https://www.sahmcapital.com/news/content/how-shutting-its-discovery-center-to-pursue-external-innovation-at-biocryst-bcrx-has-changed-its-investment-story-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T11:12:21", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZW1VQXQxeTBuZUhFWDZrRXJqcHl5MldCT1ZwdzZSd1Zmd2dfWkRta3VDZU13Q1Q3QXZXRTN5Z2JYT0dkaXRwWGpkMHZ4SWY0Ukcza2UtMDc5UWJueGdzYUxaWnlrMHM3bTFxUmxBbW1sTnN1T19sOXliX1dCWVhtTXRRTEttQUhObFZlZlc4b0NLbGVsMm5ETTJSa0tmUEo2LTRNUEFBY04yeEFyLVd3ek13TDZmWm9h?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst shuts Birmingham lab, cuts 2026 spending outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNV0hXblItUGpacTUzbV9odmNpblNVSXhScVZFenFxNFF5OHRYS3NQM1VPYnBtelQzel9RTnFsS29OWm5abzR0SC1RLUlMSW5FckV0NkhlU2FoZGctOXpWNDk5ZmNvcG9OcGZBT3ZaZFZaZlJXQUh0bkdLZWJZb0pjVUZ5M21MYWwzR1MtMmtkelQ0UVJUaEpwMEJQalhqc2pLTU1HZVExQzR3SXRiVWxiVVZPLTNaOWp1bldyUVlDcV8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocryst (NASDAQ: BCRX) director receives stock units and options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZXh4Vm5Ld21ya09McUoxZlhLaU1SRWgtYnoxM3FxSV80UDQyX1FaamNDMFlFeEdPSWZGRWVlVDZVT1dGdmZ6SFFKNk9JdEw3c1NYMndNUzc0emx3NmotQ1dKUlNvcHFRY2c0NENBZXZISlJpMDJpTUM2SFdLTFlEM2dLcFRsYm9pUDFPaU1tRkJEVlB6QmFucHE3RVZVM3dyRGczQzVkVm9UVVR3bWVwN0M2UG1qZEJOczRoUXZMaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQVGdMX3ZWLVlYYjVtdkd0YU5IVHNrb1VOVXZOdXBsZmxTRGNJRE1udGZudW5jcW4wRWtoQy1JUE51bzdKcVR0Wl8tX3FUdUZRVlcxcnZVYVkxbXpDR3ktOXpHRHlMcHJoaHc0WERGQjJtV2taYktEZ29OcVAySlF6Z1lkbVhxQ2RMVEJVR1I3a0htU0REWU1KWktRNnQ5bUZJTEJuQUhn?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock eyes growth from pediatric expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOOVdqY1lpMHdmNVZIVTFueTcyTzBlQ0w5eWVJa1RfT0FEN01RenQxUE5JOHBaZWpRamphS2x5UE5rMzdzQ2k5WGVNanZqVjEyOEdlUHFhcWlramNSdWNSaXMyak50cER2WWhUbUdBVDdFQlNxZjFzX0R2SFdnd2gwS1VLMV83ZXV6b0ZSZHozaHRjUFZhUDFBOFFTcG53ZzF4VDVid01vZTE4M2FRZU5NSFpMdW40U2J4N1FQWURuOGxlN1BoX3BOVlYtcEtCT29BRzAtd1V3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Biotech: Island Pharmaceuticals pushes deeper into US biodefence as Ebola fears spark interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxNM2ZiT0pKYWNIaVRaZ0x0OUdsNWp4TlU4LXo1WmtFTEFJMlVHU2k3V2pvMWpHU3BNN3EtT01qY0ZDNm9OWXBwb0VBTER1T2QtUzYyUXYxRE1CMmJBZ1pSTHA1QXNJbkphS3lSbW1BWjdFaEM4VXRLdkxCWDg0V1RqQnhJQnQ5Ujl6Y21hOWNuZHRJaUlaOG56TVRtVlJEbWFXTEliRDdBMzJxenRTMHc1V05yZVk5ajZSaUN0allHUG53cUNRTmFfZmN0NkpsVUJWV3ZwWmN6OFgwSDBhNEhTMkVtVnVvY1hMNmxQYkFrZEFXYWZZd2xkSFk5QUhhRGJs?oc=5", "source_name": "Proactive financial news", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock eyes growth path", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVmZXbjFXNDU5OUZfVWdhNWJJc1FxTTdmUW9vTG5kcVNFZ0JkQTB3M3haaExSdm41UDhkYjJtRElJX21xUVdIenFRb1R4a0R1UWNSc19nY3VYSkg3S3hxbXBvQW5LLUM4N0dIaGNONW9ZaVduNm5zd0JSY0NJOUVKdE9KNFNmUkFSUVBaczBfV1hXdkFUWGVlWEdHd1Rub3h0d2Rzc3VqY3E2MVM0akFZdm1OeWdhei1OdkZB?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock gains ground on pediatric approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOU3dZbUVYaG84bktObG53cWlzSm1KbHpVMHF6TW1xb3V5Z3JWR2JzT0pRelFlME1pWW1zM1J6czc3RXJNbVRvcUd0YWZtdDM4M1JVbXRMOTJHNUdGSGlremozU0c1RmxrbnNSSVZEX0VHc2pTVnJyWkJWMTBZdFRVTXhBTzJnQUIyemtxZE11WE1OUGlsMEIteVdBOTFFUnVrYlhXWlN1SnJPU2E2a0JFWksySDBPU09DWHZGaDVPYlA2UEYzRFFFeFRuaW81WVg1SG9r?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock aims for profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNLVJ1V0swYlltT3FkMWNPX1JYdnFqSW9WV1VOcG5LVmZRQkVJRXZLdmc4Nm55a1haa19ZdnVkeG0wX3dSVllILU9CTWV1R2NVMnJGU0kwM29TQllwcmFjQXJRdmF5TGFWeDlrWFJhLUU2UlVHamlvanJZVElxZ1VhMURmc2RtM3ZobXJabEtjazJzNHBaWVp6U2oyRzR0ZnpRMUpQOUNkRTJmZENFS05vNEJyZmlBTzhzZU51dVpyQU1TT3c?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst\u2019s Navenibart Deal And Pediatric Data Shape HAE Investment Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPMGNZdG0wd05aZ2V6dWVRc3hnLXZVSDdxazU1Rk1pQzB4aVR2d0ZHV05TM3Z6R2V2bFZJTzlpMHBlYmxQazM4SGRWRDVPOWhhTWhvS1M2T1JFMzhDZkVENk81V2VsWnVBcGgyVExIOFp2c3ExMU1YVEpIZjhrdUtCb2xLTjVCMUo5enRpaC1zenkyYU1waHRqcWpIWjVXQkNyanlIYVNieXBKV09OOUdWN3VPOTFfakdxdWNOblF0Zl94c2lnY3U1ZlpQWkM3THFmUTEtaWtSS3k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOYTYyMklCZ1MxRVVxamxCN3lMbmVrT0txVkdwajllbFY5YnJoVUZKN3hwNWhTZlYtLXA5Tnp5NjZVOFR6ZXRPQ2pXdnNlajNjSU84ZEhiNW81U0N0ejdNY1dPNTFaaHhsbU8xcDJmXzcyZEV4emRLbWVCVzZHT1VoTHB2R09NUlVIOVpPeU1aVzI?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxOX0paYkgyRlpPR1JWY2cxNUdqYTUyTXpkMWdRb1ZfYTQ4VDAwVzFjVFM4TnVZelVOZDdkbTh6NzI1bGVoaWVFTW9NMHkyUmdxNl9XNU9WZEhDMUlHbGdVWXBDX1pPMFl6OUo1RzZ2eldkR2pJY1RNSnBXMVJmS0sxSnZIRk1JLVBVdExGWlVUY3JKRlN6N1p1eGppX3liX3JZSmxHUkFMNy1COElyc2xHakx1cUVmODFFRVR1T3JjQkpGTHB1V0NuRkVWcVZONEt6SGctenM0a084SEZsZERhcS02bC04cTg5blJGdDVNQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Quarterly Loss Of US$721.8m Challenges Bullish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPX2JudVdjbDlHNWRjZllxOXV3dnR6NGJWRmlHLUxEWGxTOE03U2V6cFNiQVo0eGZFakdxdmpvbEVFYnN1cWJuWGVsMzZCUV9jZlhyMG1vWE1haEJ0dlhwS1NXS2N4WkhTS1c5Y3Q1WV9ublB3ZHkwM3JaTU1QbDNaV0t3c1JLOTlmRnhpN2N3N3VwVjgtQklOS2cxWGRzLU1UQ2hQZDBEc2pVSnlJ?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQMElucG5qbHNWRWFiVHp4TU0yRGRTWkpGT1o2aXhDUEdvTEpZSjFkdkxjcC1iblFOV3hTRWthT2lJYW11aGE3WU1TZklTdWZDeTZMQXVDZ1RzNnd1cG1WOHZ2VXkwcDc5aExzOXpTYXlnR3drdGItMFpialY4dWRzd3E2MGk2SVZ0d3VodnRCZHBySGJ4b3BpZTV1ejdHNzNFMEtpa3VB?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Soars 13% on Acquisition Buzz", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNd0l6ZFM5MERoWlM3RVlfaGFvMWJ2V21vQjU5eUlYZnNlaG1RNG1lVTc5NElGOGlPcjR2ckdfQUNoVkQwZjlWMDdUWDR6V1ZvUHlRcXhMdnFjU05jeUthOE1lcXRCaHN6dmVCeHZsMFhjeHA1OTdrNGs2REhEaVJIbmszNkJTWG8?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioCryst Appoints David W. Jenkins as Chief Scientific Officer", "summary": "BioCryst Pharmaceuticals has announced the appointment of David W. Jenkins as its new Chief Scientific Officer. This strategic hire is expected to bolster the company's research and development initiatives. Jenkins brings a wealth of experience to the role, which will be crucial ", "url": "https://www.moomoo.com/news/post/73006044/biocryst-appoints-david-w-jenkins-as-chief-scientific-officer?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T12:17:28", "published_display": "15 Jul 2026 12:17", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst\u2019s New Science Chief Brings Over 20 Years in Biopharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOTmx5djVrLXlfdE9GS25tc21CTWZYanpIak9XLV9xRTdfaEZsT1VQakRmVUR1cW9Zc3VHVUdvaUpzQ1dURHN6TEZ2WFdLd0NZSUdEelNHYWdYT3pDV2UzU0I0UzJaNTlEdGJVSWtvc0RTa0o5WTZFY3FEUUdNaHdCN0tpSjkxQWs5S3pCQVNxYjZ6aUwxNENXbzJRR1J4YTRZc3VMajNjY19YWllBZ2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:04:58+00:00", "published_display": "15 Jul 2026 11:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst names David Jenkins as chief scientific officer", "summary": "BioCryst Pharmaceuticals has appointed David Jenkins as its new Chief Scientific Officer, effective immediately. Jenkins, with over 20 years of experience, will lead external innovation and partnerships for rare disease therapies, signaling a strategic shift for BioCryst. The com", "url": "https://www.investing.com/news/company-news/biocryst-names-david-jenkins-as-chief-scientific-officer-93CH-4792915", "source_name": "Investing.com", "published_at": "2026-07-15T11:17:28", "published_display": "15 Jul 2026 11:17", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Appoints David Jenkins as Chief Scientific Officer | BCRX Stock News", "summary": "BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed David W. Jenkins, MA, PhD, as its first Chief Scientific Officer, effective immediately. Dr. Jenkins, with over 20 years of biopharmaceutical R&D experience, will lead a research team focused on external innovation, capabiliti", "url": "https://www.stocktitan.net/news/BCRX/bio-cryst-appoints-david-w-jenkins-as-chief-scientific-k0283wflxy2s.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:17:28", "published_display": "15 Jul 2026 11:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals Names David W. Jenkins Chief Scientific Officer to Lead External Innovation Strategy", "summary": "BioCryst Pharmaceuticals has appointed David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, a role focused on leading external innovation and partnerships to accelerate the development of rare disease therapies. Dr. Jenkins, with over 20 years of biopharmaceutical indu", "url": "https://www.quiverquant.com/news/BioCryst+Pharmaceuticals+Names+David+W.+Jenkins+Chief+Scientific+Officer+to+Lead+External+Innovation+Strategy", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T11:13:00", "published_display": "15 Jul 2026 11:13", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure", "summary": "BioCryst Pharmaceuticals (BCRX) stock appears undervalued despite a 40% five-year decline, trading at a P/S ratio of 2.8x compared to an industry average of 11.2x. The company's shift towards external innovation and partnerships, coupled with takeover speculation, suggests potent", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/biocryst-bcrx-stock-looks-like-a-bargain-after-facility-clos", "source_name": "Simply Wall Street", "published_at": "2026-07-15T01:10:33", "published_display": "15 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-biocryst-135503464.html", "source_name": "Zacks", "published_at": "2026-07-14T13:55:03+00:00", "published_display": "14 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Coverage Resumed by JPMorgan with Neutral Rating", "summary": "JPMorgan has resumed coverage of BioCryst Pharmaceuticals, Inc. (BCRX) with a Neutral rating and a $12 price target, noting that significant appreciation hinges on the successful launch of navenibart. The company holds a GF Score of 66/100, indicating moderate potential for long-", "url": "https://www.gurufocus.com/news/8954989/biocryst-bcrx-coverage-resumed-by-jpmorgan-with-neutral-rating", "source_name": "GuruFocus", "published_at": "2026-07-13T10:39:53", "published_display": "13 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes BioCryst Pharma stock coverage with neutral rating By Investing.com", "summary": "JPMorgan has resumed coverage of BioCryst Pharma (NASDAQ:BCRX) with a Neutral rating and a $12.00 price target for December 2027. The firm's outlook is based on BioCryst's strategic shift to a business development-driven model, particularly following the acquisition of Astria and", "url": "https://ca.investing.com/news/stock-market-news/jpmorgan-resumes-biocryst-pharma-stock-coverage-with-neutral-rating-93CH-4730322", "source_name": "Investing.com Canada", "published_at": "2026-07-13T08:39:53", "published_display": "13 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Cantor Global Healthcare Conference 2025 Summary", "summary": "BioCryst Pharmaceuticals (BCRX) provided an update at the Cantor Global Healthcare Conference 2025, highlighting strong growth projections for its drug ORLADEYO, with anticipated sales reaching $580\u2013$600 million this year and potentially $1 billion by the decade's end. The compan", "url": "https://quartr.com/events/biocryst-pharmaceuticals-inc-bcrx-cantor-global-healthcare-conference-2025_of73Ufyy", "source_name": "Quartr", "published_at": "2026-07-13T07:40:43", "published_display": "13 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Proxy filing Summary", "summary": "BioCryst Pharmaceuticals' (BCRX) proxy filing outlines the agenda for its Annual Meeting on June 11, 2026, which includes the election of three directors, ratification of Ernst & Young LLP as auditors, an advisory vote on executive compensation, and approval of an amended Stock I", "url": "https://quartr.com/events/biocryst-pharmaceuticals-inc-bcrx-proxy-filing_of73yeJk", "source_name": "Quartr", "published_at": "2026-07-13T07:40:43", "published_display": "13 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus", "summary": "BioCryst Pharmaceuticals (BCRX) is discontinuing internal discovery programs and closing its Discovery Center of Excellence to refocus R&D efforts. Despite mixed long-term returns, the stock is considered 50.9% undervalued with a fair value of $21.30, largely due to strong revenu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/biocryst-pharmaceuticals-bcrx-reshapes-r-and-d-as-fair-value/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-13T01:40:44", "published_display": "13 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow, S&P 500, Nasdaq Futures Flip Early Gains As Iran Talk Optimism Cools: Why VCX, MU, BCRX, CMCL, DKNG Are Trending After-Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQTjZPS01ORmdHdnNxYmJKeTNYSnRrVHBvUXZWNnViSFNGQnJwNTlVa1V1QTZDUy1XOFJ2Rmdfek5xbDZwNnZqbE1LQjZscHVVbFlOck02S3NXeWNWWHZDeXl3TVUtcGptNnVBN1dIN0NOaFRiZVplYnJucUV1VmZtWUIwcHlNSWF5bVJvb3VtT1h1cWRNc2J0a0tJVkZFWTlpZ3ZSajRIYVlmMUczUjNfc2dBaVhDOGplbFJqdlk3empaOV9YbTVfWm9mejloRkd3ZjNUYlhIYW4xM3Yw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T17:34:29+00:00", "published_display": "12 Jul 2026 17:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(BCRX) Movement Within Algorithmic Entry Frameworks", "summary": "This article from Stock Traders Daily discusses Biocryst Pharmaceuticals Inc. (BCRX) and presents various algorithmic trading strategies. It highlights strong sentiment across all horizons supporting an overweight bias, with no resistance levels identified above the current price", "url": "https://news.stocktradersdaily.com/news_release/78/BCRX_Movement_Within_Algorithmic_Entry_Frameworks_071126103002_1783823402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T22:09:41", "published_display": "11 Jul 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?", "summary": "BioCryst Pharmaceuticals announced it would discontinue its internal drug discovery programs and close its Birmingham Discovery Center by the end of 2026, shifting towards external innovation and partnerships for its rare disease pipeline. This strategic pivot aims to create a mo", "url": "https://www.sahmcapital.com/news/content/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durable-rare-disease-innovation-model-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-11T00:40:55", "published_display": "11 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock information for BioCryst Pharmaceuticals Inc. (BCRX), including its current stock price and recent performance. It also indicates that there are currently no analyst ratings or detailed earnings information available for the company. The page is part", "url": "https://timothysykes.com/quote/BCRX/", "source_name": "timothysykes.com", "published_at": "2026-07-10T00:11:28", "published_display": "10 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNeGtsSFM2bTB5MlJ2UU1ZOXdWZjJkdkZCZjhQaDhPTlgzWkJvOHNaeWJ0Mk5OdDVVZndETUZkbFNuTElacktTVlZwSk12Vm11M2w1Ul9TdzltQXFXb0ZNVGJPZ0ZoZ1RZSmJLRXhzUVFZRVl3QjZpbmIyTjBDbXlWT05ZUVJVbDlfSVVIalhPTHhjZTFDVU0xakQxTkI?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:13:23+00:00", "published_display": "09 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?", "summary": "Shares of Penguin Solutions Inc. (PENG), Arista Networks Inc. (ANET), and Biocryst Pharmaceuticals Inc. (BCRX) reached 52-week highs due to positive catalysts and increased price targets from Wall Street analysts. PENG benefited from increased AI demand and analyst upgrades, ANET", "url": "https://www.tradingview.com/news/stocktwits:13544c290094b:0-why-did-peng-anet-bcrx-shares-surge-to-52-week-highs/", "source_name": "TradingView", "published_at": "2026-07-09T03:39:32", "published_display": "09 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOR3JkbnhDbkU5SkRrUkxyYjlORVBoVWRyNzNacWFGdWkwbUZiM3loUWUwdTZOZjVRWFJkUTZrRkxlTTZYRkQ5YTdTR0p4M3B5SHZBbnlSb0t0WEJMQnRpNEFGQ3pITHlzRDVEZ2JzdzdHQzNhc1VkWkc5RzFvdGh1eVFYQVp5ZzJoQ1hHb3lRZHJqVVZFWXVSQURpRy1jWU8wWnI3UDJ4VQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T02:11:00+00:00", "published_display": "09 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?", "summary": "BioCryst Pharmaceuticals (BCRX) shares surged 8.1% due to strong performance of its marketed therapies like Orladeyo and Rapivab, and a promising rare disease-focused pipeline. The company is expected to post favorable quarterly earnings and revenue growth, with positive trends i", "url": "https://finance.yahoo.com/markets/stocks/articles/biocryst-bcrx-surges-8-1-141400956.html", "source_name": "Market source", "published_at": "2026-07-08T14:10:51", "published_display": "08 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD", "summary": "BioCryst Pharmaceuticals (BCRX) stock reached a 52-week high of $10.94, reflecting a 22.01% increase over the last year and strong recent momentum with a 30% year-to-date gain. Despite this, InvestingPro analysis suggests the stock might be overvalued. The company recently report", "url": "https://www.investing.com/news/company-news/biocryst-pharmaceuticals-stock-hits-52week-high-at-1094-usd-93CH-4779927", "source_name": "Investing.com", "published_at": "2026-07-08T00:10:52", "published_display": "08 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD By Investing.com", "summary": "BioCryst Pharmaceuticals Inc. (BCRX) stock recently hit a new 52-week high of $10.94, marking a 22.01% increase over the last year and strong year-to-date and six-month returns. This surge reflects investor confidence and strategic company advancements, despite a significant Q1 2", "url": "https://m.au.investing.com/news/stock-market-news/biocryst-pharmaceuticals-stock-hits-52week-high-at-1094-usd-93CH-4521911?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-07T20:41:07", "published_display": "07 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery, Is The Stock Still Undervalued?", "summary": "BioCryst Pharmaceuticals (BCRX) is transitioning its research model by concluding internal discovery programs and focusing on externally sourced rare disease projects. Despite a 39.85% decrease in its 5-year total shareholder return, the stock has seen recent gains of 17.0% (30-d", "url": "https://www.sahmcapital.com/news/content/biocryst-pharmaceuticals-bcrx-ends-internal-discovery-is-the-stock-still-undervalued-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-07T12:10:15", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for BioCryst Pharmaceuticals (NASDAQ:BCRX) to $14 from $13, while reiterating an Outperform rating on the stock. This adjustment suggests an updated positive outlook from the firm regarding BioCryst's future performance.", "url": "https://www.moomoo.com/news/post/72582569/rbc-capital-adjusts-biocryst-pharmaceuticals-price-target-to-14-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T11:41:07", "published_display": "07 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCRX - Biocryst Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a comprehensive overview of BioCryst Pharmaceuticals Inc. (BCRX), detailing its recent stock performance, key financial metrics, volatility indicators, and various valuation ratios. It covers aspects from market capitalization and sales to insider ownership ", "url": "https://finviz.com/stock?t=BCRX&ta=1&p=d&ty=ocv&r=m3&ov=list_strike&s=3", "source_name": "Finviz", "published_at": "2026-07-05T23:39:09", "published_display": "05 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Biocryst Pharmaceuticals Inc (BCRX)", "summary": "This article examines the historical returns of investing $1,000 in Biocryst Pharmaceuticals Inc (BCRX) over 1, 5, and 10 years, noting a 12.3% total return in the last year and a 235.8% return over ten years. It provides annual performance data for BCRX against the S&P 500 and a", "url": "https://www.stocktitan.net/tools/stock-return-calculator/BCRX", "source_name": "Stock Titan", "published_at": "2026-07-04T07:11:07", "published_display": "04 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharmaceutical company closing Birmingham facility", "summary": "BioCryst Pharmaceuticals, a North Carolina-based company founded in Birmingham, announced it will close its Birmingham Discovery Center of Excellence facility and discontinue internal discovery programs by the end of the year. The company plans to shift its focus to external rese", "url": "https://www.al.com/business/2026/06/pharmaceutical-company-closing-birmingham-facility.html", "source_name": "AL.com", "published_at": "2026-07-02T23:43:47", "published_display": "02 Jul 2026 23:43", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to nine newly-hired employees. These grants, totaling 33,950 stock options and 91,750 RSUs, were made on July 1, 2026, as inducements in accordance wit", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377418/amp", "source_name": "The Manila Times", "published_at": "2026-07-02T19:40:34", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story", "summary": "BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Birmingham Discovery Center, shifting its focus to externally sourced innovation for its rare disease pipeline. This move redefines the company's investment narrative, emphasizing execution ", "url": "https://www.sahmcapital.com/news/content/how-shutting-its-discovery-center-to-pursue-external-innovation-at-biocryst-bcrx-has-changed-its-investment-story-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T11:12:21", "published_display": "02 Jul 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZW1VQXQxeTBuZUhFWDZrRXJqcHl5MldCT1ZwdzZSd1Zmd2dfWkRta3VDZU13Q1Q3QXZXRTN5Z2JYT0dkaXRwWGpkMHZ4SWY0Ukcza2UtMDc5UWJueGdzYUxaWnlrMHM3bTFxUmxBbW1sTnN1T19sOXliX1dCWVhtTXRRTEttQUhObFZlZlc4b0NLbGVsMm5ETTJSa0tmUEo2LTRNUEFBY04yeEFyLVd3ek13TDZmWm9h?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst shuts Birmingham lab, cuts 2026 spending outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNV0hXblItUGpacTUzbV9odmNpblNVSXhScVZFenFxNFF5OHRYS3NQM1VPYnBtelQzel9RTnFsS29OWm5abzR0SC1RLUlMSW5FckV0NkhlU2FoZGctOXpWNDk5ZmNvcG9OcGZBT3ZaZFZaZlJXQUh0bkdLZWJZb0pjVUZ5M21MYWwzR1MtMmtkelQ0UVJUaEpwMEJQalhqc2pLTU1HZVExQzR3SXRiVWxiVVZPLTNaOWp1bldyUVlDcV8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biocryst (NASDAQ: BCRX) director receives stock units and options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZXh4Vm5Ld21ya09McUoxZlhLaU1SRWgtYnoxM3FxSV80UDQyX1FaamNDMFlFeEdPSWZGRWVlVDZVT1dGdmZ6SFFKNk9JdEw3c1NYMndNUzc0emx3NmotQ1dKUlNvcHFRY2c0NENBZXZISlJpMDJpTUM2SFdLTFlEM2dLcFRsYm9pUDFPaU1tRkJEVlB6QmFucHE3RVZVM3dyRGczQzVkVm9UVVR3bWVwN0M2UG1qZEJOczRoUXZMaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQVGdMX3ZWLVlYYjVtdkd0YU5IVHNrb1VOVXZOdXBsZmxTRGNJRE1udGZudW5jcW4wRWtoQy1JUE51bzdKcVR0Wl8tX3FUdUZRVlcxcnZVYVkxbXpDR3ktOXpHRHlMcHJoaHc0WERGQjJtV2taYktEZ29OcVAySlF6Z1lkbVhxQ2RMVEJVR1I3a0htU0REWU1KWktRNnQ5bUZJTEJuQUhn?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock eyes growth from pediatric expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOOVdqY1lpMHdmNVZIVTFueTcyTzBlQ0w5eWVJa1RfT0FEN01RenQxUE5JOHBaZWpRamphS2x5UE5rMzdzQ2k5WGVNanZqVjEyOEdlUHFhcWlramNSdWNSaXMyak50cER2WWhUbUdBVDdFQlNxZjFzX0R2SFdnd2gwS1VLMV83ZXV6b0ZSZHozaHRjUFZhUDFBOFFTcG53ZzF4VDVid01vZTE4M2FRZU5NSFpMdW40U2J4N1FQWURuOGxlN1BoX3BOVlYtcEtCT29BRzAtd1V3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Biotech: Island Pharmaceuticals pushes deeper into US biodefence as Ebola fears spark interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxNM2ZiT0pKYWNIaVRaZ0x0OUdsNWp4TlU4LXo1WmtFTEFJMlVHU2k3V2pvMWpHU3BNN3EtT01qY0ZDNm9OWXBwb0VBTER1T2QtUzYyUXYxRE1CMmJBZ1pSTHA1QXNJbkphS3lSbW1BWjdFaEM4VXRLdkxCWDg0V1RqQnhJQnQ5Ujl6Y21hOWNuZHRJaUlaOG56TVRtVlJEbWFXTEliRDdBMzJxenRTMHc1V05yZVk5ajZSaUN0allHUG53cUNRTmFfZmN0NkpsVUJWV3ZwWmN6OFgwSDBhNEhTMkVtVnVvY1hMNmxQYkFrZEFXYWZZd2xkSFk5QUhhRGJs?oc=5", "source_name": "Proactive financial news", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock eyes growth path", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVmZXbjFXNDU5OUZfVWdhNWJJc1FxTTdmUW9vTG5kcVNFZ0JkQTB3M3haaExSdm41UDhkYjJtRElJX21xUVdIenFRb1R4a0R1UWNSc19nY3VYSkg3S3hxbXBvQW5LLUM4N0dIaGNONW9ZaVduNm5zd0JSY0NJOUVKdE9KNFNmUkFSUVBaczBfV1hXdkFUWGVlWEdHd1Rub3h0d2Rzc3VqY3E2MVM0akFZdm1OeWdhei1OdkZB?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock gains ground on pediatric approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOU3dZbUVYaG84bktObG53cWlzSm1KbHpVMHF6TW1xb3V5Z3JWR2JzT0pRelFlME1pWW1zM1J6czc3RXJNbVRvcUd0YWZtdDM4M1JVbXRMOTJHNUdGSGlremozU0c1RmxrbnNSSVZEX0VHc2pTVnJyWkJWMTBZdFRVTXhBTzJnQUIyemtxZE11WE1OUGlsMEIteVdBOTFFUnVrYlhXWlN1SnJPU2E2a0JFWksySDBPU09DWHZGaDVPYlA2UEYzRFFFeFRuaW81WVg1SG9r?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals\u2019 SWOT analysis: stock aims for profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNLVJ1V0swYlltT3FkMWNPX1JYdnFqSW9WV1VOcG5LVmZRQkVJRXZLdmc4Nm55a1haa19ZdnVkeG0wX3dSVllILU9CTWV1R2NVMnJGU0kwM29TQllwcmFjQXJRdmF5TGFWeDlrWFJhLUU2UlVHamlvanJZVElxZ1VhMURmc2RtM3ZobXJabEtjazJzNHBaWVp6U2oyRzR0ZnpRMUpQOUNkRTJmZENFS05vNEJyZmlBTzhzZU51dVpyQU1TT3c?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst\u2019s Navenibart Deal And Pediatric Data Shape HAE Investment Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPMGNZdG0wd05aZ2V6dWVRc3hnLXZVSDdxazU1Rk1pQzB4aVR2d0ZHV05TM3Z6R2V2bFZJTzlpMHBlYmxQazM4SGRWRDVPOWhhTWhvS1M2T1JFMzhDZkVENk81V2VsWnVBcGgyVExIOFp2c3ExMU1YVEpIZjhrdUtCb2xLTjVCMUo5enRpaC1zenkyYU1waHRqcWpIWjVXQkNyanlIYVNieXBKV09OOUdWN3VPOTFfakdxdWNOblF0Zl94c2lnY3U1ZlpQWkM3THFmUTEtaWtSS3k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOYTYyMklCZ1MxRVVxamxCN3lMbmVrT0txVkdwajllbFY5YnJoVUZKN3hwNWhTZlYtLXA5Tnp5NjZVOFR6ZXRPQ2pXdnNlajNjSU84ZEhiNW81U0N0ejdNY1dPNTFaaHhsbU8xcDJmXzcyZEV4emRLbWVCVzZHT1VoTHB2R09NUlVIOVpPeU1aVzI?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxOX0paYkgyRlpPR1JWY2cxNUdqYTUyTXpkMWdRb1ZfYTQ4VDAwVzFjVFM4TnVZelVOZDdkbTh6NzI1bGVoaWVFTW9NMHkyUmdxNl9XNU9WZEhDMUlHbGdVWXBDX1pPMFl6OUo1RzZ2eldkR2pJY1RNSnBXMVJmS0sxSnZIRk1JLVBVdExGWlVUY3JKRlN6N1p1eGppX3liX3JZSmxHUkFMNy1COElyc2xHakx1cUVmODFFRVR1T3JjQkpGTHB1V0NuRkVWcVZONEt6SGctenM0a084SEZsZERhcS02bC04cTg5blJGdDVNQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals (BCRX) Quarterly Loss Of US$721.8m Challenges Bullish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPX2JudVdjbDlHNWRjZllxOXV3dnR6NGJWRmlHLUxEWGxTOE03U2V6cFNiQVo0eGZFakdxdmpvbEVFYnN1cWJuWGVsMzZCUV9jZlhyMG1vWE1haEJ0dlhwS1NXS2N4WkhTS1c5Y3Q1WV9ublB3ZHkwM3JaTU1QbDNaV0t3c1JLOTlmRnhpN2N3N3VwVjgtQklOS2cxWGRzLU1UQ2hQZDBEc2pVSnlJ?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQMElucG5qbHNWRWFiVHp4TU0yRGRTWkpGT1o2aXhDUEdvTEpZSjFkdkxjcC1iblFOV3hTRWthT2lJYW11aGE3WU1TZklTdWZDeTZMQXVDZ1RzNnd1cG1WOHZ2VXkwcDc5aExzOXpTYXlnR3drdGItMFpialY4dWRzd3E2MGk2SVZ0d3VodnRCZHBySGJ4b3BpZTV1ejdHNzNFMEtpa3VB?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioCryst (BCRX) Soars 13% on Acquisition Buzz", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNd0l6ZFM5MERoWlM3RVlfaGFvMWJ2V21vQjU5eUlYZnNlaG1RNG1lVTc5NElGOGlPcjR2ckdfQUNoVkQwZjlWMDdUWDR6V1ZvUHlRcXhMdnFjU05jeUthOE1lcXRCaHN6dmVCeHZsMFhjeHA1OTdrNGs2REhEaVJIbmszNkJTWG8?oc=5", "source_name": "Market source", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 48, "sentiment_summary": {"positive": 22, "negative": 4, "neutral": 22, "score": 58, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 10.45, "latest_week": "2026-07-10", "one_week_move": 6.2, "four_week_move": 20.1, "twelve_week_move": 10.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.224735, "market_dynamics_buy_signal": false, "relative_strength": 10.591859, "fair_value_gap": 40.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.3145, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.2% over one week, +20.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "Investing.com", "count": 6}, {"label": "Sahm", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Deals and strategy", "count": 4}, {"label": "Earnings", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.2% over one week, +20.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "BioCryst Appoints David W. Jenkins as Chief Scientific Officer"}], "updated_at": "2026-07-16T10:43:15.630041+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}